DK167113B1 - Analogifremgangsmaade til fremstilling af 3-hydroxydodecahydrobenz(e)inden-7-on-derivater - Google Patents

Analogifremgangsmaade til fremstilling af 3-hydroxydodecahydrobenz(e)inden-7-on-derivater Download PDF

Info

Publication number: DK167113B1
Authority: DK; Denmark
Prior art keywords: carbon atoms; compound; alkyl; methyl; day
Prior art date: 1981-02-23

Application number

DK075282A

Other languages

Danish (da)

English (en)

Other versions

DK75282A (da

Inventor

Marie-Madelaine Bouton

Jean Jacques

Andre Pierdet

Original Assignee

Roussel Uclaf

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1981-02-23

Filing date

1982-02-22

Publication date

1993-08-30

1982-02-22 Application filed by Roussel Uclaf filed Critical Roussel Uclaf

1982-08-24 Publication of DK75282A publication Critical patent/DK75282A/da

1993-08-30 Application granted granted Critical

1993-08-30 Publication of DK167113B1 publication Critical patent/DK167113B1/da

Links

238000000034 method Methods 0.000 title claims abstract description 8
238000002360 preparation method Methods 0.000 title claims description 5
150000001875 compounds Chemical class 0.000 claims abstract description 36
125000002252 acyl group Chemical group 0.000 claims abstract description 3
125000004432 carbon atom Chemical group C* 0.000 claims abstract 10
125000000217 alkyl group Chemical group 0.000 claims abstract 6
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 8
229920006395 saturated elastomer Polymers 0.000 claims description 2
-1 4-pyridinylcarbonyl Chemical group 0.000 claims 1
125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 claims 1
239000002253 acid Substances 0.000 claims 1
125000001931 aliphatic group Chemical group 0.000 claims 1
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 1
241001465754 Metazoa Species 0.000 abstract description 5
230000002280 anti-androgenic effect Effects 0.000 abstract description 4
239000000203 mixture Substances 0.000 abstract description 4
229910052739 hydrogen Inorganic materials 0.000 abstract 3
239000001257 hydrogen Substances 0.000 abstract 3
125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 3
125000003342 alkenyl group Chemical group 0.000 abstract 2
125000000304 alkynyl group Chemical group 0.000 abstract 2
125000005842 heteroatom Chemical group 0.000 abstract 2
150000001732 carboxylic acid derivatives Chemical class 0.000 abstract 1
239000003937 drug carrier Substances 0.000 abstract 1
125000002485 formyl group Chemical group [H]C(*)=O 0.000 abstract 1
231100000252 nontoxic Toxicity 0.000 abstract 1
230000003000 nontoxic effect Effects 0.000 abstract 1
239000000546 pharmaceutical excipient Substances 0.000 abstract 1
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 12
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 12
PDMMFKSKQVNJMI-BLQWBTBKSA-N Testosterone propionate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](OC(=O)CC)[C@@]1(C)CC2 PDMMFKSKQVNJMI-BLQWBTBKSA-N 0.000 description 12
229960001712 testosterone propionate Drugs 0.000 description 12
210000000056 organ Anatomy 0.000 description 8
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 6
JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 6
210000004907 gland Anatomy 0.000 description 6
239000000243 solution Substances 0.000 description 6
VLQPTWRGZFDXMO-UHFFFAOYSA-N inden-4-one Chemical compound O=C1C=CC=C2C=CC=C12 VLQPTWRGZFDXMO-UHFFFAOYSA-N 0.000 description 5
WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 4
241000699800 Cricetinae Species 0.000 description 4
HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 4
230000005764 inhibitory process Effects 0.000 description 4
WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical class [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 3
ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
239000004480 active ingredient Substances 0.000 description 3
229940079593 drug Drugs 0.000 description 3
239000003814 drug Substances 0.000 description 3
230000000144 pharmacologic effect Effects 0.000 description 3
210000002307 prostate Anatomy 0.000 description 3
UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 3
239000002904 solvent Substances 0.000 description 3
238000003756 stirring Methods 0.000 description 3
230000004584 weight gain Effects 0.000 description 3
235000019786 weight gain Nutrition 0.000 description 3
VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 2
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
150000008064 anhydrides Chemical class 0.000 description 2
YHASWHZGWUONAO-UHFFFAOYSA-N butanoyl butanoate Chemical compound CCCC(=O)OC(=O)CCC YHASWHZGWUONAO-UHFFFAOYSA-N 0.000 description 2
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
208000035475 disorder Diseases 0.000 description 2
230000000694 effects Effects 0.000 description 2
238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 2
239000008194 pharmaceutical composition Substances 0.000 description 2
239000002244 precipitate Substances 0.000 description 2
239000000047 product Substances 0.000 description 2
239000000741 silica gel Substances 0.000 description 2
229910002027 silica gel Inorganic materials 0.000 description 2
239000000126 substance Substances 0.000 description 2
HMUNWXXNJPVALC-UHFFFAOYSA-N 1-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperazin-1-yl]-2-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)N1CCN(CC1)C(CN1CC2=C(CC1)NN=N2)=O HMUNWXXNJPVALC-UHFFFAOYSA-N 0.000 description 1
SXAMGRAIZSSWIH-UHFFFAOYSA-N 2-[3-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]-1,2,4-oxadiazol-5-yl]-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C1=NOC(=N1)CC(=O)N1CC2=C(CC1)NN=N2 SXAMGRAIZSSWIH-UHFFFAOYSA-N 0.000 description 1
WZFUQSJFWNHZHM-UHFFFAOYSA-N 2-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperazin-1-yl]-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)N1CCN(CC1)CC(=O)N1CC2=C(CC1)NN=N2 WZFUQSJFWNHZHM-UHFFFAOYSA-N 0.000 description 1
YJLUBHOZZTYQIP-UHFFFAOYSA-N 2-[5-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]-1,3,4-oxadiazol-2-yl]-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C1=NN=C(O1)CC(=O)N1CC2=C(CC1)NN=N2 YJLUBHOZZTYQIP-UHFFFAOYSA-N 0.000 description 1
HAMJKXVQKYMNFN-UHFFFAOYSA-N 3H-inden-1-yl butanoate Chemical compound C(CCC)(=O)OC1=CCC2=CC=CC=C12 HAMJKXVQKYMNFN-UHFFFAOYSA-N 0.000 description 1
CONKBQPVFMXDOV-QHCPKHFHSA-N 6-[(5S)-5-[[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperazin-1-yl]methyl]-2-oxo-1,3-oxazolidin-3-yl]-3H-1,3-benzoxazol-2-one Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)N1CCN(CC1)C[C@H]1CN(C(O1)=O)C1=CC2=C(NC(O2)=O)C=C1 CONKBQPVFMXDOV-QHCPKHFHSA-N 0.000 description 1
208000002874 Acne Vulgaris Diseases 0.000 description 1
206010020112 Hirsutism Diseases 0.000 description 1
206010062767 Hypophysitis Diseases 0.000 description 1
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
229920002472 Starch Polymers 0.000 description 1
WETWJCDKMRHUPV-UHFFFAOYSA-N acetyl chloride Chemical compound CC(Cl)=O WETWJCDKMRHUPV-UHFFFAOYSA-N 0.000 description 1
239000012346 acetyl chloride Substances 0.000 description 1
206010000496 acne Diseases 0.000 description 1
150000001266 acyl halides Chemical class 0.000 description 1
239000000654 additive Substances 0.000 description 1
230000001548 androgenic effect Effects 0.000 description 1
239000008365 aqueous carrier Substances 0.000 description 1
235000019445 benzyl alcohol Nutrition 0.000 description 1
239000003153 chemical reaction reagent Substances 0.000 description 1
238000007796 conventional method Methods 0.000 description 1
239000006071 cream Substances 0.000 description 1
239000013078 crystal Substances 0.000 description 1
HTWWKYKIBSHDPC-UHFFFAOYSA-N decanoyl decanoate Chemical compound CCCCCCCCCC(=O)OC(=O)CCCCCCCCC HTWWKYKIBSHDPC-UHFFFAOYSA-N 0.000 description 1
239000002270 dispersing agent Substances 0.000 description 1
238000001035 drying Methods 0.000 description 1
239000003480 eluent Substances 0.000 description 1
239000003995 emulsifying agent Substances 0.000 description 1
239000000839 emulsion Substances 0.000 description 1
239000000706 filtrate Substances 0.000 description 1
239000007903 gelatin capsule Substances 0.000 description 1
150000002334 glycols Chemical class 0.000 description 1
230000003779 hair growth Effects 0.000 description 1
150000002440 hydroxy compounds Chemical class 0.000 description 1
125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
238000001727 in vivo Methods 0.000 description 1
239000011261 inert gas Substances 0.000 description 1
239000008101 lactose Substances 0.000 description 1
239000006210 lotion Substances 0.000 description 1
239000003921 oil Substances 0.000 description 1
235000019198 oils Nutrition 0.000 description 1
239000012074 organic phase Substances 0.000 description 1
239000012188 paraffin wax Substances 0.000 description 1
DUCKXCGALKOSJF-UHFFFAOYSA-N pentanoyl pentanoate Chemical compound CCCCC(=O)OC(=O)CCCC DUCKXCGALKOSJF-UHFFFAOYSA-N 0.000 description 1
230000002093 peripheral effect Effects 0.000 description 1
210000003635 pituitary gland Anatomy 0.000 description 1
239000003755 preservative agent Substances 0.000 description 1
WYVAMUWZEOHJOQ-UHFFFAOYSA-N propionic anhydride Chemical compound CCC(=O)OC(=O)CC WYVAMUWZEOHJOQ-UHFFFAOYSA-N 0.000 description 1
ATBIAJXSKNPHEI-UHFFFAOYSA-N pyridine-3-carbonyl chloride Chemical compound ClC(=O)C1=CC=CN=C1 ATBIAJXSKNPHEI-UHFFFAOYSA-N 0.000 description 1
239000008159 sesame oil Substances 0.000 description 1
235000011803 sesame oil Nutrition 0.000 description 1
229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
235000017557 sodium bicarbonate Nutrition 0.000 description 1
239000008107 starch Substances 0.000 description 1
235000019698 starch Nutrition 0.000 description 1
239000007858 starting material Substances 0.000 description 1
238000010254 subcutaneous injection Methods 0.000 description 1
239000007929 subcutaneous injection Substances 0.000 description 1
239000000829 suppository Substances 0.000 description 1
230000009885 systemic effect Effects 0.000 description 1
230000000699 topical effect Effects 0.000 description 1
235000019871 vegetable fat Nutrition 0.000 description 1
238000009736 wetting Methods 0.000 description 1
239000000080 wetting agent Substances 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/79—Acids; Esters
- C07D213/80—Acids; Esters in position 3
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C49/00—Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
- C07C49/385—Saturated compounds containing a keto group being part of a ring
- C07C49/487—Saturated compounds containing a keto group being part of a ring containing hydroxy groups
- C07C49/507—Saturated compounds containing a keto group being part of a ring containing hydroxy groups polycyclic
- C07C49/513—Saturated compounds containing a keto group being part of a ring containing hydroxy groups polycyclic a keto group being part of a condensed ring system
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
- C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
- C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D317/70—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with ring systems containing two or more relevant rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
- C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
- C07D317/72—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 spiro-condensed with carbocyclic rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2603/00—Systems containing at least three condensed rings
- C07C2603/02—Ortho- or ortho- and peri-condensed systems
- C07C2603/04—Ortho- or ortho- and peri-condensed systems containing three rings
- C07C2603/06—Ortho- or ortho- and peri-condensed systems containing three rings containing at least one ring with less than six ring members
- C07C2603/10—Ortho- or ortho- and peri-condensed systems containing three rings containing at least one ring with less than six ring members containing five-membered rings
- C07C2603/12—Ortho- or ortho- and peri-condensed systems containing three rings containing at least one ring with less than six ring members containing five-membered rings only one five-membered ring
- C07C2603/16—Benz[e]indenes; Hydrogenated benz[e]indenes

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Bioinformatics & Cheminformatics (AREA)
Pharmacology & Pharmacy (AREA)
Engineering & Computer Science (AREA)
Animal Behavior & Ethology (AREA)
Chemical Kinetics & Catalysis (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Dermatology (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Pyridine Compounds (AREA)
Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
Cosmetics (AREA)
Steroid Compounds (AREA)

DK075282A 1981-02-23 1982-02-22 Analogifremgangsmaade til fremstilling af 3-hydroxydodecahydrobenz(e)inden-7-on-derivater DK167113B1 (da)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
FR8103520A FR2500441A1 (fr)	1981-02-23	1981-02-23	Nouveaux medicaments derives de la 3-hydroxy dodecahydro benz (e) inden-7-one, produits derives de la 3-hydroxy dodecahydro benz (e) inden-7-one et leur procede de preparation
FR8103520		1981-02-23

Publications (2)

Publication Number	Publication Date
DK75282A DK75282A (da)	1982-08-24
DK167113B1 true DK167113B1 (da)	1993-08-30

Family

ID=9255514

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK075282A DK167113B1 (da)	1981-02-23	1982-02-22	Analogifremgangsmaade til fremstilling af 3-hydroxydodecahydrobenz(e)inden-7-on-derivater

Country Status (11)

Country	Link
US (5)	US4466971A (mo)
EP (1)	EP0059146B1 (mo)
JP (2)	JPS57156430A (mo)
AT (1)	ATE15761T1 (mo)
AU (1)	AU547375B2 (mo)
CA (1)	CA1195982A (mo)
DE (1)	DE3266460D1 (mo)
DK (1)	DK167113B1 (mo)
FR (1)	FR2500441A1 (mo)
IE (1)	IE52327B1 (mo)
ZA (1)	ZA821001B (mo)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR2500441A1 (fr) *	1981-02-23	1982-08-27	Roussel Uclaf	Nouveaux medicaments derives de la 3-hydroxy dodecahydro benz (e) inden-7-one, produits derives de la 3-hydroxy dodecahydro benz (e) inden-7-one et leur procede de preparation
TW224048B (mo) *	1992-03-30	1994-05-21	Hoechst Roussel Pharma
DE60032780T2 (de)	1999-10-14	2007-11-08	Kaken Pharmaceutical Co., Ltd.	Tetrahydroquinolin-derivate

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR1359675A (fr) *	1963-01-14	1964-04-30	Roussel Uclaf	Nouveaux composés tricycliques et procédé de préparation
US3499912A (en) *	1963-11-06	1970-03-10	Hoffmann La Roche	Process for the preparation of 5-oxo-11alpha-hydroxy - 3,5 - seco-a-nor-pregnan-3-oic acid - 3,11 lactones and derivatives thereof
US3956316A (en) *	1964-09-29	1976-05-11	Hoffmann-La Roche Inc.	11-Substituted-desA-pregnanes and derivatives thereof
US3412107A (en) *	1964-09-29	1968-11-19	Hoffmann La Roche	11-hydroxy-5-oxo-3, 5-seco-a-nor-androstan-3-oic acid 3, 11-lactones
CH558343A (de) *	1965-03-25	1975-01-31	Hoffmann La Roche	Verfahren zur herstellung von 9(beta),10(alpha)-steroiden.
US3574688A (en) *	1966-03-22	1971-04-13	Roussel Uclaf	Unsaturated 2-oxa steroid derivatives and process for their preparation
US3496199A (en) *	1968-06-17	1970-02-17	Hoffmann La Roche	Process for the preparation of 9beta,10alpha-steroids
US3984473A (en) *	1968-10-04	1976-10-05	Hoffmann-La Roche Inc.	Stereospecific total steroidal synthesis via substituted C/D-trans indanones
US3984474A (en) *	1975-05-30	1976-10-05	E. R. Squibb & Sons, Inc.	4,5-Secoandrostanes
JPS5538316A (en) *	1978-09-08	1980-03-17	Takeda Chem Ind Ltd	Intermediate for synthesis of steroid and its preparation
CA1195997A (en) *	1979-02-23	1985-10-29	Andor Furst	Dea-steroids
FR2500441A1 (fr) *	1981-02-23	1982-08-27	Roussel Uclaf	Nouveaux medicaments derives de la 3-hydroxy dodecahydro benz (e) inden-7-one, produits derives de la 3-hydroxy dodecahydro benz (e) inden-7-one et leur procede de preparation

1981
- 1981-02-23 FR FR8103520A patent/FR2500441A1/fr active Granted
1982
- 1982-02-16 ZA ZA821001A patent/ZA821001B/xx unknown
- 1982-02-18 DE DE8282400285T patent/DE3266460D1/de not_active Expired
- 1982-02-18 EP EP82400285A patent/EP0059146B1/fr not_active Expired
- 1982-02-18 AT AT82400285T patent/ATE15761T1/de not_active IP Right Cessation
- 1982-02-19 US US06/350,151 patent/US4466971A/en not_active Expired - Lifetime
- 1982-02-22 AU AU80699/82A patent/AU547375B2/en not_active Ceased
- 1982-02-22 DK DK075282A patent/DK167113B1/da not_active IP Right Cessation
- 1982-02-22 CA CA000396753A patent/CA1195982A/fr not_active Expired
- 1982-02-23 IE IE379/82A patent/IE52327B1/en not_active IP Right Cessation
- 1982-02-23 JP JP57026928A patent/JPS57156430A/ja active Granted
1983
- 1983-10-19 US US06/543,315 patent/US4607054A/en not_active Expired - Lifetime
1986
- 1986-04-24 US US06/855,905 patent/US4849454A/en not_active Expired - Lifetime
1988
- 1988-07-25 US US07/223,636 patent/US4927975A/en not_active Expired - Lifetime
1990
- 1990-02-09 JP JP2028621A patent/JPH02243646A/ja active Granted
- 1990-03-30 US US07/502,922 patent/US5158981A/en not_active Expired - Lifetime

Also Published As

Publication number	Publication date
US4849454A (en)	1989-07-18
ZA821001B (en)	1983-01-26
JPH02243646A (ja)	1990-09-27
US5158981A (en)	1992-10-27
FR2500441A1 (fr)	1982-08-27
EP0059146A1 (fr)	1982-09-01
US4927975A (en)	1990-05-22
FR2500441B1 (mo)	1984-10-19
JPS57156430A (en)	1982-09-27
JPH0420893B2 (mo)	1992-04-07
US4607054A (en)	1986-08-19
AU547375B2 (en)	1985-10-17
IE820379L (en)	1982-08-23
DK75282A (da)	1982-08-24
AU8069982A (en)	1982-09-02
CA1195982A (fr)	1985-10-29
ATE15761T1 (de)	1985-10-15
DE3266460D1 (en)	1985-10-31
IE52327B1 (en)	1987-09-16
EP0059146B1 (fr)	1985-09-25
US4466971A (en)	1984-08-21
JPH0466855B2 (mo)	1992-10-26

Legal Events

Date	Code	Title	Description
1993-08-30	B1	Patent granted (law 1993)
2002-03-11	PUP	Patent expired

Publication	Publication Date	Title
DE68917884T2 (de)	1995-03-23	Phosphinsäure-Derivate von Steroiden als 5-alpha-Reduktase-Inhibitoren.
PT2503005E (pt)	2015-12-09	17alfa-propionato de cortexolona na forma cristalina de hidrato iv
JPH04330088A (ja)	1992-11-18	グリチルレチン酸誘導体
UA45311C2 (uk)	2002-04-15	16<font face="Symbol">a</font>,17-ЦИКЛОГЕКСИЛМЕТИЛЕНДІОКСИ-11<font face="Symbol">b</font>,21-ДИГІДРОКСИПРЕГНА-1,4-ДІЄН-3,20-ДІОН, СПОСІБ ЙОГО ОДЕРЖАННЯ, ЛІКАРСЬКИЙ ЗАСІБ
NO138199B (no)	1978-04-17	Barkemaskin av trommeltypen.
HK60297A (en)	1997-05-16	Androstane 17-carboxylic-acid esters, their preparation and medicaments containing them
EP0558416B1 (fr)	1996-05-22	Nouveaux stéroides comportant en position 17 un radical méthylène lactone, leur procédé et des intermédiaires de préparation, leur application comme médicaments et les compositions pharmaceutiques les renfermant
EP0071153B1 (de)	1986-09-10	Neue Androstan-Derivate, Verfahren zu ihrer Herstellung und pharmazeutische Präparate, die diese Verbindungen enthalten
FI77668B (fi)	1988-12-30	Foerfarande foer framstaellning av nya 16 -metyl-pregnanseriens diklorderivat.
US4410459A (en)	1983-10-18	Process for preparation of cytostatic compounds
US4218446A (en)	1980-08-19	Substituted steroid-spiro-oxazolidinone derivatives and a process for the preparation thereof
DK143757B (da)	1981-10-05	Analogifremgangsmaade til fremstilling af 16,16-disubstituerede 3-oxoandrostener
Bowers et al.	1959	Steroids. CX. 1 Studies in Nitro Steroids (Part 2). 1 A New Route to 6-Nitro Steroid Hormones. 6α-Nitro-17α-acetoxyprogesterone and 6α-Nitrocortisone2
EP0101659A2 (fr)	1984-02-29	Nouveaux dérivés d'amino-14 stéroides, procédé pour leur préparation, et application en thérapeutique
US2906758A (en)	1959-09-29	3-(hydroxyalkyl)-ethers of estradiol
EP0059146B1 (fr)	1985-09-25	Nouveaux médicaments dérivés de la 3-hydroxy dodécahydro benz (e) inden-7-one, produits dérivés de la 3-hydroxy dodécahydro benz (e) inden-7-one et leur procédé de préparation
Litvinovskaya et al.	2025	Synthesis of tetraesters of indolyl-3-acetic acid with 24-epibrassinosteroids and their influence on the initial growth of wheat plants
US3743660A (en)	1973-07-03	17-sulfo-acetates of estradiol
SI9620030A (sl)	1998-02-28	17-difluormetilen-estratrieni
EP0685442A1 (fr)	1995-12-06	Réactif utile pour et procédé pour la synthèse d'ester et xanthate transestérifiable
US3975412A (en)	1976-08-17	Mono-acylation of 17-hydroxy-3-alkoxygona-2,5-(10)dienes
SU1001860A3 (ru)	1983-02-28	Способ получени производных хлорамбуцила (его варианты)
US3297720A (en)	1967-01-10	Synthesis of steroids
EP0239500A2 (fr)	1987-09-30	Dérivés de la 1-styrène sulfonyl 2-oxo 5-hydroxy pyrrolidine, leur procédé et des intermédiaires de préparation, leur application comme médicaments et les compositions les renfermant
CZ288297B6 (en)	2001-05-16	17-Deoxycortikoid-21-esters of carboxylic acids, process of their preparation and pharmaceutical preparations in which they are comprised